[Diltiazem and modulation of platelet aggregation].
The calcium antagonists including Diltiazem have been proved to inhibit platelet aggregation caused by ADP. In order to demonstrate the anti-aggregant properties of Diltiazem, a study was conducted on the aggregation curves in blood samples from 20 healthy subjects before and after a week's treatment with 240 mg oral Diltiazem per diem. The experiment confirmed the anti-aggregant properties of Diltiazem which is therefore useful in the treatment of cardiovascular disease given its capacity to dilate the coronary arteries and inhibit platelet aggregation.